This company listing is no longer active
Roche Holding Inkomsten in het verleden
Verleden criteriumcontroles 5/6
De winst van Roche Holding is gedaald met een gemiddeld jaarlijks percentage van -8.5%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks daalde met 4.6%. De inkomsten zijn daalde met een gemiddeld percentage van 0.4% per jaar. Het rendement op het eigen vermogen Roche Holding bedraagt 36.4% en de nettomarge bedraagt 20.3%.
Belangrijke informatie
-8.54%
Groei van de winst
-6.83%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 16.33% |
| Inkomstengroei | -0.44% |
| Rendement op eigen vermogen | 36.43% |
| Nettomarge | 20.33% |
| Volgende winstupdate | 23 Jul 2026 |
Recente prestatie-updates uit het verleden
Recent updates
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.Opbrengsten en kosten
Hoe Roche Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 25 | 63,356 | 12,880 | 13,767 | 12,535 |
| 30 Sep 25 | 63,422 | 11,155 | 13,786 | 12,847 |
| 30 Jun 25 | 63,488 | 9,429 | 13,804 | 13,158 |
| 31 Mar 25 | 62,942 | 8,853 | 13,739 | 13,265 |
| 31 Dec 24 | 62,395 | 8,277 | 13,674 | 13,372 |
| 30 Sep 24 | 61,488 | 9,448 | 13,510 | 13,377 |
| 30 Jun 24 | 60,581 | 10,619 | 13,346 | 13,381 |
| 31 Mar 24 | 60,511 | 11,059 | 13,416 | 13,463 |
| 31 Dec 23 | 60,441 | 11,498 | 13,486 | 13,545 |
| 30 Sep 23 | 61,486 | 11,263 | 13,690 | 13,669 |
| 30 Jun 23 | 62,530 | 11,028 | 13,894 | 13,793 |
| 31 Mar 23 | 64,172 | 11,725 | 13,793 | 13,696 |
| 31 Dec 22 | 65,814 | 12,421 | 13,691 | 13,599 |
| 30 Sep 22 | 66,716 | 13,539 | 13,262 | 13,592 |
| 30 Jun 22 | 67,617 | 14,657 | 12,833 | 13,585 |
| 31 Mar 22 | 66,734 | 14,294 | 12,405 | 13,804 |
| 31 Dec 21 | 65,850 | 13,930 | 11,977 | 14,022 |
| 30 Sep 21 | 63,974 | 13,975 | 12,037 | 13,747 |
| 30 Jun 21 | 62,098 | 14,019 | 12,097 | 13,472 |
| 31 Mar 21 | 61,221 | 14,157 | 12,026 | 13,019 |
| 31 Dec 20 | 60,343 | 14,295 | 11,954 | 12,566 |
| 30 Sep 20 | 61,361 | 13,626 | 12,289 | 12,382 |
| 30 Jun 20 | 62,378 | 12,957 | 12,624 | 12,198 |
| 31 Mar 20 | 63,065 | 13,227 | 12,904 | 12,061 |
| 31 Dec 19 | 63,751 | 13,497 | 13,183 | 11,923 |
| 30 Sep 19 | 62,736 | 12,654 | 13,275 | 11,702 |
| 30 Jun 19 | 61,721 | 11,810 | 12,933 | 11,480 |
| 31 Mar 19 | 60,609 | 11,155 | 12,800 | 11,337 |
| 31 Dec 18 | 59,497 | 10,500 | 12,667 | 11,194 |
| 30 Sep 18 | 58,611 | 10,483 | 12,641 | 11,005 |
| 30 Jun 18 | 57,725 | 10,465 | 12,615 | 10,815 |
| 31 Mar 18 | 56,736 | 9,549 | 12,322 | 10,672 |
| 31 Dec 17 | 55,746 | 8,633 | 12,029 | 10,529 |
| 30 Sep 17 | 54,961 | 9,154 | 11,148 | 10,411 |
| 30 Jun 17 | 54,176 | 9,675 | 10,266 | 10,293 |
| 31 Mar 17 | 53,406 | 9,626 | 10,305 | 10,172 |
| 31 Dec 16 | 52,636 | 9,576 | 10,343 | 10,050 |
| 30 Sep 16 | 52,109 | 9,332 | 10,655 | 9,975 |
| 30 Jun 16 | 51,581 | 9,087 | 10,966 | 9,900 |
| 31 Mar 16 | 50,992 | 8,975 | 10,953 | 9,678 |
| 31 Dec 15 | 50,403 | 8,863 | 10,940 | 9,455 |
| 30 Sep 15 | 50,364 | 8,908 | 10,978 | 9,305 |
| 30 Jun 15 | 50,324 | 8,953 | 11,004 | 9,155 |
| 31 Mar 15 | 50,095 | 9,143 | 10,924 | 9,068 |
Kwaliteitswinsten: ROG heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (20.3%) ROG } zijn hoger dan vorig jaar (13.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van ROG is de afgelopen 5 jaar met 8.5% per jaar gedaald.
Versnelling van de groei: De winstgroei van ROG over het afgelopen jaar ( 55.6% ) overtreft het 5-jarig gemiddelde ( -8.5% per jaar).
Winst versus industrie: De winstgroei ROG over het afgelopen jaar ( 55.6% ) overtrof de Pharmaceuticals -sector 30.9%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 36.4% ) van ROG wordt als hoog beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/03/16 17:34 |
| Aandelenkoers aan het einde van de dag | 2026/03/16 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Roche Holding AG wordt gevolgd door 44 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |